Ofer Shpilberg

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/11047150/publications.pdf

Version: 2024-02-01

179 papers	11,938 citations	50170 46 h-index	27345 106 g-index
179 all docs	179 docs citations	179 times ranked	10825 citing authors

#	Article	IF	Citations
1	CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncology, The, 2006, 7, 379-391.	5.1	1,840
2	Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma. New England Journal of Medicine, 2008, 359, 906-917.	13.9	1,787
3	Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era. Journal of Clinical Oncology, 2010, 28, 4184-4190.	0.8	1,331
4	CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncology, The, 2011, 12, 1013-1022.	5.1	633
5	Bortezomib Plus Melphalan and Prednisone Compared With Melphalan and Prednisone in Previously Untreated Multiple Myeloma: Updated Follow-Up and Impact of Subsequent Therapy in the Phase III VISTA Trial. Journal of Clinical Oncology, 2010, 28, 2259-2266.	0.8	403
6	Persistent Overall Survival Benefit and No Increased Risk of Second Malignancies With Bortezomib-Melphalan-Prednisone Versus Melphalan-Prednisone in Patients With Previously Untreated Multiple Myeloma. Journal of Clinical Oncology, 2013, 31, 448-455.	0.8	250
7	Rituximab Maintenance Therapy After Autologous Stem-Cell Transplantation in Patients With Relapsed CD20⁺ Diffuse Large B-Cell Lymphoma: Final Analysis of the Collaborative Trial in Relapsed Aggressive Lymphoma. Journal of Clinical Oncology, 2012, 30, 4462-4469.	0.8	248
8	Rituximab Maintenance for the Treatment of Patients With Follicular Lymphoma: Systematic Review and Meta-analysis of Randomized Trials. Journal of the National Cancer Institute, 2009, 101, 248-255.	3.0	227
9	ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). Annals of Oncology, 2013, 24, 561-576.	0.6	193
10	Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era. Blood, 2020, 135, 1929-1945.	0.6	191
11	Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study. Lancet Oncology, The, 2008, 9, 435-444.	5.1	190
12	Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents. Journal of Clinical Oncology, 2016, 34, 2988-2996.	0.8	190
13	Positron Emission Tomographyâ€“Computed Tomography (PET-CT) After Induction Therapy Is Highly Predictive of Patient Outcome in Follicular Lymphoma: Analysis of PET-CT in a Subset of PRIMA Trial Participants. Journal of Clinical Oncology, 2011, 29, 3194-3200.	0.8	176
14	Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. Lancet, The, 2019, 394, 2271-2281.	6.3	155
15	VMP (Bortezomib, Melphalan, and Prednisone) Is Active and Well Tolerated in Newly Diagnosed Patients With Multiple Myeloma With Moderately Impaired Renal Function, and Results in Reversal of Renal Impairment: Cohort Analysis of the Phase III VISTA Study. Journal of Clinical Oncology, 2009, 27, 6086-6093.	0.8	154
16	Intravenous Versus Oral Iron Supplementation for the Treatment of Anemia in CKD: Systematic Review and Meta-analysis. American Journal of Kidney Diseases, 2008, 52, 897-906.	2.1	147
17	Immunoglobulin Prophylaxis in Hematopoietic Stem Cell Transplantation: Systematic Review and Meta-Analysis. Journal of Clinical Oncology, 2009, 27, 770-781.	0.8	140
18	Rituximab Maintenance for the Treatment of Patients With Follicular Lymphoma: An Updated Systematic Review and Meta-analysis of Randomized Trials. Journal of the National Cancer Institute, 2011, 103, 1799-1806.	3.0	131

#	Article	IF	Citations
19	Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study. European Journal of Haematology, 2011, 86, 23-31.	1.1	126
20	Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (antiâ€“IL-6) in multiple myeloma. Blood, 2014, 123, 4136-4142.	0.6	125
21	Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: <scp>ELOQUENT</scp>â€2 followâ€up and postâ€hoc analyses on progressionâ€free survival and tumour growth. British Journal of Haematology, 2017, 178, 896-905.	1.2	120
22	Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing. Nature Medicine, 2021, 27, 491-503.	15.2	118
23	The late adverse events of rituximab therapy â€“ rare but there!. Leukemia and Lymphoma, 2009, 50, 1083-1095.	0.6	116
24	Gold nanoparticles stabilize peptide-drug-conjugates for sustained targeted drug delivery to cancer cells. Journal of Nanobiotechnology, 2018, 16, 34.	4.2	106
25	Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone. Blood, 2010, 116, 3743-3750.	0.6	101
26	Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial. Lancet Oncology, The, 2011, 12, 773-784.	5.1	98
27	Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial. Lancet Oncology, The, 2018, 19, 1530-1542.	5.1	91
28	Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study. Blood Cancer Journal, 2020, 10, 91.	2.8	90
29	LOW MOLECULAR WEIGHT HEPARIN FOR THE PREVENTION OF VENO-OCCLUSIVE DISEASE OF THE LIVER IN BONE MARROW TRANSPLANTATION PATIENTS1. Transplantation, 1996, 61, 1067-1071.	0.5	90
30	Current Multiple Myeloma Treatment Strategies with Novel Agents: A European Perspective. Oncologist, 2010, 15, 6-25.	1.9	85
31	Comparison of Subcutaneous Versus Intravenous Administration of Rituximab As Maintenance Treatment for Follicular Lymphoma: Results From a Two-Stage, Phase IB Study. Journal of Clinical Oncology, 2014, 32, 1782-1791.	0.8	84
32	Intravenous iron supplementation for the treatment of chemotherapy-induced anaemia â€“ systematic review and meta-analysis of randomised controlled trials. Acta OncolÃ³gica, 2013, 52, 18-29.	0.8	82
33	Serum albumin level at diagnosis of diffuse large Bâ€cell lymphoma: an important simple prognostic factor. Hematological Oncology, 2016, 34, 184-192.	0.8	80
34	Downregulation of Mir-31, Mir-155, and Mir-564 in Chronic Myeloid Leukemia Cells. PLoS ONE, 2012, 7, e35501.	1.1	79
35	Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalanâ€“prednisone vs. melphalanâ€“prednisone in the phase III VISTA trial in multiple myeloma. European Journal of Haematology, 2011, 86, 372-384.	1.1	77
36	MiR-30e induces apoptosis and sensitizes K562 cells to imatinib treatment via regulation of the BCRâ€“ABL protein. Cancer Letters, 2015, 356, 597-605.	3.2	75

#	Article	IF	Citations
37	Hematopoietic growth factors in aplastic anemia patients treated with immunosuppressive therapy-systematic review and meta-analysis. Haematologica, 2009, 94, 712-719.	1.7	74
38	Familial aggregation of haematological neoplasms: a controlled study. British Journal of Haematology, 1994, 87, 75-80.	1.2	73
39	Ibrutinib resistance in mantle cell lymphoma: clinical, molecular and treatment aspects. British Journal of Haematology, 2018, 181, 306-319.	1.2	70
40	Randomized Phase II Study of Bortezomib, Thalidomide, and Dexamethasone With or Without Cyclophosphamide As Induction Therapy in Previously Untreated Multiple Myeloma. Journal of Clinical Oncology, 2013, 31, 247-255.	0.8	69
41	Cannabidiol for the Prevention of Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplantation: Results ofÂa Phase II Study. Biology of Blood and Marrow Transplantation, 2015, 21, 1770-1775.	2.0	61
42	Rituximabâ€associated acute thrombocytopenia: An underâ€diagnosed phenomenon. American Journal of Hematology, 2009, 84, 247-250.	2.0	59
43	Neutropenia after rituximab treatment. Current Opinion in Hematology, 2012, 19, 32-38.	1.2	58
44	Restoration of miR-424 suppresses BCRâ€“ABL activity and sensitizes CML cells to imatinib treatment. Cancer Letters, 2015, 360, 245-256.	3.2	55
45	Increased risk of salivary gland tumors after low-dose irradiation. Laryngoscope, 1998, 108, 1095-1097.	1.1	52
46	Rituximab maintenance improves overall survival of patients with follicular lymphomaâ€”Individual patient data meta-analysis. European Journal of Cancer, 2017, 76, 216-225.	1.3	50
47	Meta-analysis of autologous bone marrow transplantation versus chemotherapy in adult patients with acute myeloid leukemia in first remission. Leukemia Research, 2004, 28, 605-612.	0.4	48
48	Final Results of a Phase II Trial of Belinostat (PXD101) in Patients with Recurrent or Refractory Peripheral or Cutaneous T-Cell Lymphoma.. Blood, 2009, 114, 920-920.	0.6	38
49	Pre-Transplant Immunological Profile and Risk Factor Analysis of Post-Transplant Lymphoproliferative Disease Development: The Results of a Nested Matched Case-Control Study. Leukemia and Lymphoma, 1999, 36, 109-121.	0.6	34
50	Transient normal platelet counts and decreased requirement for interferon during pregnancy in essential thrombocythaemia. British Journal of Haematology, 1996, 92, 491-493.	1.2	33
51	A molecular mechanism for mimosine-induced apoptosis involving oxidative stress and mitochondrial activation. Apoptosis: an International Journal on Programmed Cell Death, 2008, 13, 147-155.	2.2	33
52	Has the time for first-line treatment with second generation tyrosine kinase inhibitors in patients with chronic myelogenous leukemia already come? Systematic review and meta-analysis. Haematologica, 2013, 98, 95-102.	1.7	31
53	Modification of initial therapy in early and advanced Hodgkin lymphoma, based on interim <scp>PET</scp>/<scp>CT</scp> is beneficial: a prospective multicentre trial of 355 patients. British Journal of Haematology, 2017, 178, 709-718.	1.2	31
54	Adenomatous polyposis coli I1307K mutation in Jewish patients with different ethnicity. Cancer, 2000, 88, 755-760.	2.0	30

#	Article	IF	Citations
55	Mycophenolate mofetil vs. methotrexate for the prevention of graft-versus-host-disease â€“ Systematic review and meta-analysis. Leukemia Research, 2014, 38, 352-360.	0.4	29
56	Prevalence of iron deficiency and anemia among strenuously trained adolescents. Journal of Adolescent Health, 2005, 37, 220-223.	1.2	26
57	Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5â€year followâ€up. British Journal of Haematology, 2015, 171, 344-354.	1.2	26
58	COVID-19 among patients with hematological malignancies: a national Israeli retrospective analysis with special emphasis on treatment and outcome. Leukemia and Lymphoma, 2021, 62, 3384-3393.	0.6	25
59	Acute leukemia relapse presenting as central diabetes insipidus. Cancer, 1994, 73, 2312-2316.	2.0	24
60	ATG plus Cyclosporine Reduces All-Cause Mortality in Patients with Severe Aplastic Anemia â€“ Systematic Review and Meta-Analysis. Acta Haematologica, 2008, 120, 237-243.	0.7	24
61	Highâ€dose imatinib for newly diagnosed chronic phase chronic myeloid leukemia patientsâ€”Systematic review and metaâ€analysis. American Journal of Hematology, 2011, 86, 657-662.	2.0	24
62	Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial. Lancet Haematology,the, 2022, 9, e403-e414.	2.2	23
63	Updated Follow-up and Results of Subsequent Therapy in the Phase III VISTA Trial: Bortezomib Plus Melphalanâ€“Prednisone Versus Melphalanâ€“Prednisone in Newly Diagnosed Multiple Myeloma. Blood, 2008, 112, 650-650.	0.6	22
64	Eloquent-2 Update: A Phase 3, Randomized, Open-Label Study of Elotuzumab in Combination with Lenalidomide/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma - 3-Year Safety and Efficacy Follow-up. Blood, 2015, 126, 28-28.	0.6	22
65	Network analysis of microRNAs, genes and their regulation in diffuse and follicular B-cell lymphomas. Oncotarget, 2018, 9, 7928-7941.	0.8	22
66	Bendamustineâ€associated infectionsâ€”systematic review and metaâ€analysis of randomized controlled trials. Hematological Oncology, 2017, 35, 424-431.	0.8	21
67	Effect of imatinib on the signal transduction cascade regulating telomerase activity in K562 (BCR-ABLâ€“positive) cells sensitive and resistant to imatinib. Experimental Hematology, 2010, 38, 27-37.	0.2	20
68	Mechanism of the antitumoral activity of deferasirox, an iron chelation agent, on mantle cell lymphoma. Leukemia and Lymphoma, 2013, 54, 851-859.	0.6	20
69	Characteristics of initial compared with subsequent bacterial infections among hospitalised haemato-oncological patients. International Journal of Antimicrobial Agents, 2012, 40, 123-126.	1.1	19
70	The prevalence of low hemoglobin values among new infantry recruits and nonlinear relationship between hemoglobin concentration and physical fitness. American Journal of Hematology, 2007, 82, 128-133.	2.0	18
71	High incidence of silent cerebral infarcts in adult patients with beta thalassemia major. Thrombosis Research, 2016, 144, 119-122.	0.8	18
72	Chlorambucil for the treatment of patients with chronic lymphocytic leukemia (CLL) â€“ a systematic review and meta-analysis of randomized trials. Leukemia and Lymphoma, 2016, 57, 2047-2057.	0.6	18

#	Article	IF	Citations
73	Prespecified Candidate Biomarkers Identify Follicular Lymphoma Patients Who Achieved Longer Progression-Free Survival with Bortezomibâ€“Rituximab Versus Rituximab. Clinical Cancer Research, 2013, 19, 2551-2561.	3.2	16
74	Continued Overall Survival Benefit After 5 Years' Follow-up with Bortezomib-Melphalan-Prednisone (VMP) Versus Melphalan-Prednisone (MP) in Patients with Previously Untreated Multiple Myeloma, and No Increased Risk of Second Primary Malignancies: Final Results of the Phase 3 VISTA Trial. Blood, 2011, 118, 476-476.	0.6	16
75	Remission of Malabsorption in Congenital Intestinal Lymphangiictasia Following Chemotherapy for Lymphoma. Leukemia and Lymphoma, 1993, 11, 147-148.	0.6	15
76	Second-generation tyrosine kinase inhibitors reduce telomerase activity in K562 cells. Cancer Letters, 2012, 323, 223-231.	3.2	14
77	Salvage therapy of refractory and relapsed acute leukemia with high dose mitoxantrone and high dose cytarabine. Leukemia Research, 1999, 23, 695-700.	0.4	13
78	Incidence of Anemia and Iron Deficiency in Strenuously Trained Adolescents: Results of a Longitudinal Follow-Up Study. Journal of Adolescent Health, 2009, 45, 286-291.	1.2	13
79	Characterization of haematological parameters with bortezomibâ€“melphalanâ€“prednisone versus melphalanâ€“prednisone in newly diagnosed myeloma, with evaluation of longâ€term outcomes and risk of thromboembolic events with use of erythropoiesisâ€stimulating agents: analysis of the VISTA trial. British Journal of Haematology, 2011, 153, 212-221.	1.2	13
80	BurkittÂ's Lymphoma of the Ovary: Case Report and Review of the Literature. Acta Haematologica, 2013, 129, 169-174.	0.7	13
81	Superior Outcomes Associated with Complete Response: Analysis of the Phase III VISTA Study of Bortezomib Plus Melphalanâ€“Prednisone Versus Melphalanâ€“Prednisone. Blood, 2008, 112, 2778-2778.	0.6	13
82	Independent Predictive Value of PET-CT Pre Transplant in Relapsed and Refractory Patients with CD20 Diffuse Large B-Cell Lymphoma (DLBCL) Included in the CORAL Study.. Blood, 2009, 114, 881-881.	0.6	13
83	Secular trends in the epidemiology of pediculosis capitis and pubis among Israeli soldiers: a 27-year follow-up. International Journal of Dermatology, 2001, 40, 637-639.	0.5	12
84	The antiâ€leukaemic activity of novel synthetic naphthoquinones against acute myeloid leukaemia: induction of cell death via the triggering of multiple signalling pathways. British Journal of Haematology, 2009, 147, 459-470.	1.2	12
85	High-dose cytarabine as salvage therapy for relapsed or refractory acute myeloid leukemia-is more better or more of the same?. Hematological Oncology, 2016, 34, 28-35.	0.8	12
86	Efficacy and Safety of Lenalidomide (LEN) Versus Placebo (PBO) in RBC-Transfusion Dependent (TD) Patients (Pts) with IPSS Low/Intermediate (Int-1)-Risk Myelodysplastic Syndromes (MDS) without Del(5q) and Unresponsive or Refractory to Erythropoiesis-Stimulating Agents (ESAs): Results from a Randomized Phase 3 Study (CC-5013-MDS-005). Blood, 2014, 124, 409-409.	0.6	11
87	Invasive Aspergillosis in Neutropenic Patients with Hematological Disorders. Leukemia and Lymphoma, 1991, 4, 257-262.	0.6	10
88	Does immune serum globulin confer protection against skin diseases?. International Journal of Dermatology, 2000, 39, 628-631.	0.5	10
89	First line and salvage therapy with total therapy 3-based treatment for multiple myelomaâ€“â€“An extended single center experience. Leukemia Research, 2014, 38, 1401-1406.	0.4	10
90	Extended 5-y follow-up (FU) of phase 3 ELOQUENT-2 study of elotuzumab + lenalidomide/dexamethasone (ELd) vs Ld in relapsed/refractory multiple myeloma (RRMM).. Journal of Clinical Oncology, 2018, 36, 8040-8040.	0.8	10

#	Article	IF	Citations
91	Management of Adult Patients with Acute Lymphoblastic Leukemia in First Complete Remission: Systematic Review and Meta-Analysis.. Blood, 2009, 114, 49-49.	0.6	10
92	Low molecular weight heparin stimulates megakaryocytopoiesis in bone-marrow transplantation patients. , 1996, 53, 46-48.		9
93	Retinoic acid induces adhesion and migration in NB4 cells through Pyk2 signaling. Leukemia Research, 2013, 37, 956-962.	0.4	9
94	Elevation of CRP precedes clinical suspicion of bloodstream infections in patients undergoing hematopoietic cell transplantation. Journal of Infection, 2013, 67, 194-198.	1.7	9
95	Surveillance of infectious complications in hemato-oncological patients. Israel Medical Association Journal, 2009, 11, 133-7.	0.1	9
96	Massive hematuria due to extramedullary plasmacytoma invading the bladder. Medical and Pediatric Oncology, 1993, 21, 67-69.	1.0	8
97	Multifactorial activities of nonsteroidal antiestrogens against leukemia. Cancer Detection and Prevention, 2003, 27, 389-396.	2.1	8
98	Management of Aplastic Anemia: The Role of Systematic Reviews and Meta-Analyses. Acta Haematologica, 2011, 125, 47-54.	0.7	8
99	GFR in Patients with Î²-Thalassemia Major. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 1350-1356.	2.2	8
100	High-Intensity Induction Chemotherapy Is Feasible for Elderly Patients with Acute Myeloid Leukemia. Acta Haematologica, 2016, 135, 55-64.	0.7	8
101	Randomized, placeboâ€controlled, phase 3 study of perifosine combined with bortezomib and dexamethasone in patients with relapsed, refractory multiple myeloma previously treated with bortezomib. EJHaem, 2020, 1, 94-102.	0.4	8
102	Deferasirox induces cyclin D1 degradation and apoptosis in mantle cell lymphoma in a reactive oxygen speciesâ€•and GSK3Î²â€dependent mechanism. British Journal of Haematology, 2021, 192, 747-760.	1.2	8
103	Diffuse Large B-Cell Lymphoma (DLBCL) Patients Failing Second-Line R-DHAP Or R-ICE Chemotherapy Included In The Coral Study. Blood, 2013, 122, 764-764.	0.6	8
104	Role of radiotherapy and dose-densification of R-CHOP in primary mediastinal B-cell lymphoma: A subgroup analysis of the unfolder trial of the German Lymphoma Alliance (GLA).. Journal of Clinical Oncology, 2020, 38, 8041-8041.	0.8	8
105	18F-FDG PET/MR imaging of lymphoma nodal target lesions. Medicine (United States), 2018, 97, e0490.	0.4	7
106	Dual BRAF/MEK blockade restores CNS responses in BRAF-mutant Erdheimâ€“Chester disease patients following BRAF inhibitor monotherapy. Neuro-Oncology Advances, 2020, 2, vdaa024.	0.4	7
107	Result of FDG PET-CT Imaging After Immunochemotherapy Induction Is a Powerful and Independent Prognostic Indicator of Outcome for Patients with Follicular Lymphoma: An Analysis From the PRIMA Study. Blood, 2010, 116, 855-855.	0.6	7
108	Tailoring the GVHD prophylaxis regimen according to transplantation associated toxicitiesâ€”Substituting the 3rd dose of methotrexate to mycophenolate mofetil. Leukemia Research, 2014, 38, 913-917.	0.4	6

#	Article	IF	Citations
109	Randomized Placebo-Controlled Phase III Study Of Perifosine Combined With Bortezomib and Dexamethasone In Relapsed, Refractory Multiple Myeloma Patients Previously Treated With Bortezomib. Blood, 2013, 122, 3189-3189.	0.6	6
110	Induction of death of leukemia cells by TW-74, a novel derivative of chloro-naphthoquinone. Anticancer Research, 2013, 33, 183-90.	0.5	6
111	The cyclophosphamide, vincristine, prednisone, bleomycin, doxorubicin, and procarbazine (COPBLAM-I) regimen for intermediate-grade non-Hodgkin's lymphoma. Long term follow-up in 51 patients. Cancer, 1994, 74, 3029-3033.	2.0	5
112	Re: Consolidation Therapy With Autologous Bone Marrow Transplantation in Adults With Acute Myeloid Leukemia: A Meta-analysis. Journal of the National Cancer Institute, 2004, 96, 1038-1039.	3.0	5
113	Enhanced adhesion/migration and induction of Pyk2 expression in K562 cells following imatinib exposure. Leukemia Research, 2013, 37, 1729-1736.	0.4	5
114	The Contribution of MicroRNAs to the Inflammatory and Neoplastic Characteristics of Erdheimâ€“Chester Disease. Cancers, 2020, 12, 3240.	1.7	5
115	Eltrombopag for enhancement of platelet engraftment in patients undergoing allogeneic cord blood transplantation. Leukemia and Lymphoma, 2021, 62, 2747-2754.	0.6	5
116	Phase 3 ELOQUENT-2 study: Extended four year follow-up (FU) of elotuzumab plus lenalidomide/dexamethasone (ELd) vs Ld in relapsed/refractory multiple myeloma (RRMM).. Journal of Clinical Oncology, 2017, 35, 8028-8028.	0.8	5
117	Response: Re: Rituximab Maintenance for the Treatment of Patients With Follicular Lymphoma: Systematic Review and Meta-analysis of Randomized trials. Journal of the National Cancer Institute, 2009, 101, 1289-1290.	3.0	4
118	Total therapy-based treatment for multiple myelomaâ€”a single center experience. Annals of Hematology, 2010, 89, 53-59.	0.8	4
119	Allogeneic Hematopoietic Cell Transplantation for Adult Patients with Acute Leukemia: The Role of Meta-Analyses. Acta Haematologica, 2011, 125, 39-46.	0.7	4
120	Limited Positron Emission Tomography-Computed Tomography for Restaging of Lymphoma: A Strategy for Reducing Radiation Exposure among Patients with Early-Stage Curable Lymphoma. Acta Haematologica, 2014, 131, 239-244.	0.7	4
121	CHOP-like-14 compared to CHOP-like-21 for patients with aggressive lymphoma â€“ a meta-analysis of randomized controlled trials. Acta OncolÃ³gica, 2016, 55, 77-84.	0.8	4
122	Non-Coding RNAs in Normal B-Cell Development and in Mantle Cell Lymphoma: From Molecular Mechanism to Biomarker and Therapeutic Agent Potential. International Journal of Molecular Sciences, 2021, 22, 9490.	1.8	4
123	Kydar Multicenter Trial of Quadruple Regimen for Induction Resistant Myeloma Combined with Translational Single-Cell Analysis Identifies Potential Drivers of Advanced Resistance, Including Novel Immune Checkpoints. Blood, 2019, 134, 982-982.	0.6	4
124	Erythropoiesis-Stimulating Agents Do Not Adversely Affect Long-Term Outcomes Nor Increase the Risk of Thromboembolic Events in Multiple Myeloma Patients Treated in the Phase III VISTA Trial.. Blood, 2008, 112, 1741-1741.	0.6	4
125	Bortezomib, Thalidomide, and Dexamethasone (VTD) Versus VTD Plus Cyclophosphamide as Induction Therapy in Previously Untreated Multiple Myeloma Patients Eligible for HDT-ASCT: A Randomized Phase 2 Trial.. Blood, 2009, 114, 2312-2312.	0.6	4
126	Tailored Therapy In Hodgkin Lymphoma, Based on Predefined Risk Factors and Early Interim PET/CT, Can Lead to Modification and Safe Reduction In Therapy: Results of 134 Patients on the Israel National Hodgkin Study.. Blood, 2010, 116, 2809-2809.	0.6	4

#	Article	IF	Citations
127	Molecular Mechanisms Involved in the Development of Extramedullary Disease Following the Administration of All-Trans Retinoic Acid to Patients with Acute Promyelocytic Leukemia.. Blood, 2009, 114, 1596-1596.	0.6	4
128	Molecular epidemiology of hematological neoplasmsâ€"Present status and future directions. Leukemia Research, 1997, 21, 265-284.	0.4	3
129	Familial Aggregation of Nonhematological Malignancies in Relatives of Patients with Hematological Neoplasms. Acta Haematologica, 1999, 101, 21-24.	0.7	3
130	Expedient synthesis and anticancer evaluation of dualâ€action 9â€anilinoacridine methyl triazene chimeras. Chemical Biology and Drug Design, 2021, 97, 237-252.	1.5	3
131	Bortezomib Plus Melphalanâ€"Prednisone Continues to Demonstrate a Survival Benefit Vs Melphalanâ€"Prednisone in the Phase III VISTA Trial in Previously Untreated Multiple Myeloma After 3 Years' Follow-up and Extensive Subsequent Therapy Use.. Blood, 2009, 114, 3859-3859.	0.6	3
132	Identification of Patient Subgroups Demonstrating Longer Progression-Free Survival (PFS) Benefit with Bortezomib-Rituximab Versus Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma (FL): Biomarker Analyses of the Phase 3 LYM3001 Study. Blood, 2011, 118, 265-265.	0.6	3
133	Final Results From a Phase II Trial with the First in Class Recombinant Polyclonal Antibody Product Rozrolimupab in Primary Immune Thrombocytopenia. Blood, 2011, 118, 527-527.	0.6	3
134	Cannabidiol - An Innovative Strategy For Graft Versus Host Disease Prevention. Blood, 2013, 122, 3299-3299.	0.6	3
135	Tailored Therapy in Hodgkin Lymphoma, Based on Predefined Risk Factors and Early Interim PET/CT: Israeli H2 Study. Blood, 2014, 124, 4409-4409.	0.6	3
136	Rituximab Maintenance (MR) for Patients with Mantle Cell Lymphoma (MCL) â€" a Systematic Review and Meta-Analysis of Randomized Controlled Trials (RCTs). Blood, 2014, 124, 4466-4466.	0.6	3
137	MicroRNA-15a-5p acts as a tumor suppressor in histiocytosis by mediating CXCL10-ERK-LIN28a-let-7 axis. Leukemia, 2021, , .	3.3	3
138	Postremission therapy with two different dose regimens of cytarabine in adults with acute myelogenous leukemia. Leukemia Research, 1995, 19, 893-897.	0.4	2
139	Hemato-oncology Tourism in Israel: A Retrospective Review. JCO Global Oncology, 2020, 6, 1314-1320.	0.8	2
140	The Pattern of Use of PET/CT Scans in the Clinical Management of Chronic Lymphocytic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 558-563.	0.2	2
141	Mimosine Induces Apoptosis through Metal Ion Chelation, Mitochondrial Activation and Reactive Oxygen Species Production in Human Leukemic Cells.. Blood, 2004, 104, 4481-4481.	0.6	2
142	Bendamustine Is Not Associated With An Increase In Infections â€" Systematic Review and Meta-Analysis Of Randomized Controlled Trials. Blood, 2013, 122, 5125-5125.	0.6	2
143	Outcomes in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Relapsing after Autologous Stem Cell Transplantation (ASCT): An Analysis of Patients Included in the Coral Study. Blood, 2015, 126, 517-517.	0.6	2
144	18F-FDG-PET/CT Pulmonary Infiltrates in Non-Hodgkin Lymphoma Patients Treated with Combined Immunochemotherapy: Incidence and Clinical Characteristics. Israel Medical Association Journal, 2017, 19, 372-377.	0.1	2

#	Article	IF	Citations
145	Reply to N. Reddy et al. Journal of Clinical Oncology, 2009, 27, 2297-2298.	0.8	1
146	Toxicity of autologous hematopoietic cell transplantation in patients with multiple myeloma â€“ comparison between two different induction regimens. Clinical Transplantation, 2012, 26, E549-54.	0.8	1
147	Rituximab Retreatment in B-Cell Non-Hodgkins Lymphoma Patients.. Blood, 2005, 106, 2455-2455.	0.6	1
148	Comparison between Intravenous Iron and Oral Iron Preparations for the Treatment of Anemia of Chronic Kidney Disease - A Systematic Review and Meta-Analysis. Blood, 2007, 110, 3748-3748.	0.6	1
149	Myeloid Colony-Stimulating Factors Do Not Increase the Risk of Mortality or Disease Activity Measures in Patients with Acute Myeloid Leukemia: Systematic Review and Meta-Analysis.. Blood, 2009, 114, 2045-2045.	0.6	1
150	Anthracycline-Containing Regimens for Treatment of Follicular Lymphoma In Adults: Systematic Review and Meta-Analysis.. Blood, 2010, 116, 2820-2820.	0.6	1
151	Adolescents and Young Adults with Acute Lymphoblastic Leukemia Have Better Outcomes When Treated with Pediatric-Inspired Regimens - Systematic Review and Meta-Analysis of Comparative Trials. Blood, 2011, 118, 2591-2591.	0.6	1
152	Low Vs. High Intensity BEAM Prior To Autologous Hematopoietic Cell Transplantation For Chemosensitive Lymphoma Patients - A Matched Cohort Analysis. Blood, 2013, 122, 3391-3391.	0.6	1
153	In vitro effects of a combination of zldovudine and acyclovir on growth of normal human myelold progenitor cells. American Journal of Hematology, 1996, 51, 329-330.	2.0	0
154	The MACOP-B and VACOP-B combination chemotherapy for young patients with intermediate-grade non-Hodgkinâ€™s lymphoma. Leukemia Research, 1998, 22, 997-1002.	0.4	0
155	Evidence-Based Guided Interventions in Acute Leukemia. , 0, , .		0
156	The Prevalence of Iron Deficient Anemia among New Infantry Recruits and Its Effect on Physical Fitness.. Blood, 2004, 104, 3718-3718.	0.6	0
157	TPCK Induces Apoptosis in Human Acute Myeloid Leukemia U-937 Cells.. Blood, 2004, 104, 4478-4478.	0.6	0
158	Expression of VEGF-C and Its Receptor VEGFR-3 in Diffuse Large B-Cell Lymphomas.. Blood, 2005, 106, 4666-4666.	0.6	0
159	Anemia and Iron Deficiency in Strenuously Trained Adolescents.. Blood, 2007, 110, 961-961.	0.6	0
160	Meta Analysis: Rituximab as Maintenance Therapy for Patients with Follicular Lymphoma.. Blood, 2007, 110, 3408-3408.	0.6	0
161	ATG Plus Cyclosporine-a Should Be Used as Immunosuppressive Therapy in Patients with Severe Aplastic Anemia-Systematic Review and Meta-Analysis. Blood, 2008, 112, 4120-4120.	0.6	0
162	Hematopoietic Growth Factors In Aplastic Anemia Patients Treated with Immunosuppressive Therapy: Systematic Review and Meta-Analysis - 2010 Update.. Blood, 2010, 116, 1164-1164.	0.6	0

#	Article	IF	Citations
163	Effect of the Cytochrome P450 3A4 Inducers, Rifampicin and Dexamethasone, on the Pharmacokinetic, Pharmacodynamic and Safety Profile of Bortezomib In Patients with Multiple Myeloma (MM) and Non-Hodgkin's Lymphoma (NHL). Blood, 2010, 116, 3983-3983.	0.6	0
164	Limited PET-CT May Be Adequate for Interim and End of Therapy Response Assessment in Patients with Early Stage Hodgkin and Aggressive Non-Hodgkin Lymphoma - A Retrospective Single Center Study. Blood, 2011, 118, 1562-1562.	0.6	0
165	The Role of Hematopoietic Growth Factors in Aplastic Anemia: An Evidence-Based Perspective. , 2012, , 195-210.		0
166	Post-Transplant Lymphoproliferative Disorder in Lung Transplant Recipients â€“ a Shift Lo Late Onset Disease. Blood, 2012, 120, 5075-5075.	0.6	0
167	Increased Activity of Prothrombinase Fgl-2 in Peripheral Blood Mononuclear Cells of Patients with B-Cell Lymphoma.. Blood, 2012, 120, 2665-2665.	0.6	0
168	The Role of Anti-CD33 for the Treatment of Acute Myeloid Leukemia â€“ Systematic Review and Meta-Analysis. Blood, 2012, 120, 1521-1521.	0.6	0
169	Enhanced Adhesion, Migration and Pyk2 Expression in K562 Cells Following Imatinib Treatment. Blood, 2012, 120, 4426-4426.	0.6	0
170	Low molecular weight heparin (LMWH) for primary thrombophylaxis in patients with solid malignancies: Systematic review and meta-analysis.. Journal of Clinical Oncology, 2013, 31, e20595-e20595.	0.8	0
171	Secondary Malignancies Following High Dose Therapy and Autologous Hematopoietic Cell Transplantation - Systematic Review and Meta Analysis. Blood, 2013, 122, 4633-4633.	0.6	0
172	CHOP/CHOP-Like-14 Vs. CHOP/CHOP-Like-21 For Patients With Aggressive Lymphoma â€“ a Systematic Review and Meta-Analysis Of Randomized Controlled Trials. Blood, 2013, 122, 1798-1798.	0.6	0
173	The Two Common Mutations Causing Factor XI Deficiency in Jews Stem From Distinct Founders: One of Ancient Middle Eastern Origin and Another of More Recent European Origin. Blood, 1997, 90, 2654-2659.	0.6	0
174	Individual Patient Data (IPD) Meta-Analysis of Rituximab Maintenance (MR) for Patients (pts) with Follicular Lymphoma (FL). Blood, 2014, 124, 4462-4462.	0.6	0
175	Can We Improve the Predictive Value of Interim PET/CT Using a New Prognostic Model for Advanced Hodgkin Lymphoma?. Blood, 2016, 128, 3001-3001.	0.6	0
176	Eltrombopag for Enhancement of Platelet Engraftment in Patients Undergoing Allogeneic Cord Blood Transplantation. Blood, 2018, 132, 2092-2092.	0.6	0
177	Synthesis and Biological Studies of New Multifunctional Curcumin Platforms for Anticancer Drug Delivery. Medicinal Chemistry, 2019, 15, 537-549.	0.7	0
178	A Novel Therapy-Resistance Transcriptional Signature Based on Single Cell Analysis in Kydar Clinical Trial. Blood, 2020, 136, 19-20.	0.6	0
179	Novel pyrrolidine-aminophenyl-1,4-naphthoquinones: structure-related mechanisms of leukemia cell death. Molecular and Cellular Biochemistry, 0, , .	1.4	0